On a serious note, there are new guidelines for NIHL which are present for 2016 but represent nothing more than a view point. The new guidelines have not been reviewed and critiqued by the medico-legal community and have not been judicially considered.
The new guidelines will effect the de minimis defence (claims which are too small to receive compensation). I believe this will have little or no impact on the SGH portfolio.
i.e.- Slight NIHL without tinnitus or slight tinnitus without NIHL - Up to
£5,860.00
I remain confident for the case resolutions in FY16. By my forecasts, I still believe $5oM of Fee revenue is achievable.
The medical evidence is the most critical factor in assessing all claims. Management seem reasonably confident on the due outcomes. Therefore the evidence provided must be compelling in achieving their targeted forecasts.
I just found a link for Slater & Gordon's new NIHL advertising campaign....Enjoy......
This thread is closed.
You may not reply to this discussion at this time.
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$52.65 |
Change
0.130(0.25%) |
Mkt cap ! $21.42B | |||
| Open | High | Low | Value | Volume |
| $52.98 | $54.05 | $52.59 | $32.52M | 615.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 1976 | $52.53 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $52.86 | 383 | 2 |
View Market Depth
| Last trade - 16.10pm 02/07/2025 (20 minute delay) ? |
| SGH (ASX) Chart |